英文名称 | CAS号 | 中文名 | 中文别名 | 分子式 | 分子量 | EINECS号 |
---|---|---|---|---|---|---|
Semagacestat (LY450139)
|
425386-60-3 |
司马西特
|
塞美司他;LY450139;LY-450139;LY 450139;(2S)-2-羟基-3-甲基-N-[(1S)-1-甲基-2-氧代-2-[[(1S)-2,3,4,5-四氢-3-甲基-2-氧代-1H-3-苯并氮杂卓-1-基]氨基]乙基]丁酰胺;司马西特;(2S)-2-羟基-3-甲基;司马西特;(2S)-2-羟基-3-甲基-N-[(1S)-1-甲基-2-氧代-2-[[(1S)-2,5-四氢-3-甲基-2-氧代-1H-3-苯并氮杂卓-1-基]氨基]乙基]丁酰胺
|
C19H27N3O4 |
361.44 | 1592732-453-0 |
SecinH3
|
853625-60-2 |
CS-2379
|
CS-2379
|
C24H20N4O4S |
460.5 | |
SB-705498
|
501951-42-4 |
SB-75498
|
N-(2-溴苯基)-N'-[(3R)-1-[5-(三氟甲基)-2-吡啶基]-3-吡咯烷基]脲
|
C17H16BrF3N4O |
429.23435 | |
SB273005
|
205678-31-5 |
SB2735 INTEGRIN抑制剂
|
SB273005 INTEGRIN抑制剂
|
C22H24F3N3O4 |
451.43887 | |
Salirasib
|
162520-00-5 |
Salirasib
|
2-[[(2E,6E)-3,7,11-三甲基-2,6,10-十二烷三烯-1-基]硫代]苯甲酸;反,反法尼基硫代水杨酸(SALIRASIB);2-(((2E,11-三甲基十二碳-2,10-三烯-2-基)硫基)苯甲酸;反,反法尼基硫代水杨酸;沙利雷塞;法尼基硫代水杨酸
|
C22H30O2S |
358.54 | |
Sabutoclax
|
1228108-65-3 |
SABUTOCLAX
|
|
C42H40N2O8 |
700.7756 | |
(4S)-4-[3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL]PYRROLIDIN-2-ONE
|
85416-73-5 |
S- (+)-Rolipram
|
(+)-ROLIPRAM;(S)-ROLIPRAM;(S)-4-[3-(环戊基氧基)-4-甲氧基苯基]-2-吡咯烷酮;S-(+)-咯利普兰
|
C16H21NO3 |
275.34 | |
Rotundine
|
483-14-7 |
罗通定 CP2 98+%
|
L-四氢巴马汀;罗通定 CP2000 98%;罗通定,BR;延胡索乙素;5,8,13,13A-四氢-2,3,9,10-四甲氧基-6H-二苯并[A,G]喹嗪;罗通定.左旋延胡索乙素;罗通定 CP2000
|
C21H25NO4 |
355.4275 | |
Rosiglitazone hydrochloride
|
302543-62-0 |
盐酸罗格列酮
|
盐酸罗格列酮;5-[[4-[2-(甲基-2-吡啶氨基)乙氧基]苯基]甲基]-2,4-噻唑烷二酮盐酸盐;5-(4-(2-(甲基(吡啶-2-基)氨基)乙氧基)苄基)四氢噻唑-2,4-二酮盐酸盐;ROSIGLITAZONE HYDROCHLORIDE 盐酸罗格列酮;盐酸罗格列酮(5-[[4-[2-(甲基-2-吡啶氨基)乙氧基]苯基]甲基]-2,4-噻唑烷二酮盐酸盐、罗格列酮盐酸盐);盐酸罗格列酮标准品
|
C18H19N3O3S.HCl |
393.89 | 1308068-626-2 |
ROLIPRAM
|
61413-54-5 |
诺普利兰
|
咯利普兰;SB95952;ZK62711;(R;S)-ROLIPRAM;SB 95952;ZK 62711;SB-95952;ZK-62711;咯利普兰(消旋);诺普利兰;咯利普兰;诺普利兰,一种PDE5抑制剂
|
C16H21NO3 |
275.34 | 262-771-1 |
RG2833
|
1215493-56-3 |
RG2833(RGFP19)
|
RG2833(RGFP109);N-[6-(2-氨基苯基氨基)-6-氧代己基]-4-甲基苯甲酰胺;RG2833;RGFP109;RG-2833;RGFP 109;CS-2320
|
C20H25N3O2 |
339.4314 | |
ALK5 inhibitor II
|
446859-33-2 |
ALK5 INHIBITOR
|
ALK5抑制剂;2-[3-(6-甲基-2-吡啶基)-1H-吡唑-4-基]-1,5-萘啶;2-3-(6-甲基-2-吡啶基)-1H-吡唑-4-基-1,5-萘;2-(3-(6-甲基吡啶-2-基)-1H-吡唑-4-基)-1,5-萘啶;E-616452;SJN 2511;E616452;SJN2511;E 616452;SJN-2511;CS-204
|
C17H13N5 |
287.31862 | |
Remodelin
|
1622921-15-6 |
REMODELIN
|
CS-1751;4-[2-(2-环戊基亚基肼基)-4-噻唑基]苯甲腈氢溴酸盐
|
C15H15BrN4S |
363.2754 | |
Refametinib
|
923032-37-5 |
REFAMETINIB
|
BAY 869766;BAY 86-97661;RDEA119;瑞法替尼;BAY 869766;BAY 86-9766;CS-2434;瑞法替尼;瑞美替尼
|
C19H20F3IN2O5S |
572.33718 | |
RBC 8
|
361185-42-4 |
RBC8
|
CS-2174;RBC8>98%;RBC-8;RBC 8;CS-2130
|
C25H20N4O3 |
424.4513 | |
RAF265 (CHIR-265)
|
927880-90-8 |
RAF265
|
RAF265(CHIR-265);RAF265;CHIR-265 or RAF265;1-Methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-1H-benzimidazol-2-amine;1-methyl-5-(2-(5-(trifluoromethyl)-1H-imidazol-2-yl)pyridin-4-yloxy)-N-(4-(trifluoromethyl)phenyl)-1H-benzo[d]imidazol-2-amine;1-Methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-1H-benzimidazol-2-amine RAF265 (CHIR-265);RAF 265 1-Methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-1H-benzimidazol-2-amine;1H-Benzimidazol-2-amine, 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-
|
C24H15F6N6O |
||
JNJ-26481585
|
875320-29-9 |
JNJ 26854165
|
JNJ26481585;JNJ 26481585;N-羟基-2-[4-[[[(1-甲基-1H-吲哚-3-基)甲基]氨基]甲基]-1-哌啶基]-5-嘧啶甲酰胺;CS-1098;N1-(2-(1H-吲哚-3-基)乙基)-N4-(吡啶-4-基)苯-1,4-二胺;-羟基-2-[4-[[[(1-甲基-1H-吲哚-3-基)甲基]氨基]甲基]-1-哌啶基]-5-嘧啶甲酰胺;奎诺司他
|
C21H26N6O2 |
394.47014 | |
PYR-41
|
418805-02-4 |
PYR 41
|
CS-1129;PYR41;PYR-41;4-[4-[(5-硝基-2-呋喃基)亚甲基]-3,5-二氧代-1-吡唑烷基]苯甲酸乙酯
|
C17H13N3O7 |
371.30102 | |
PTC-209 hydrobromide
|
1217022-63-3 |
PTC-29HBR
|
PTC-209HBR;CS-1314;PTC-209HBR
|
C17H14Br3N5OS |
576.10296 | |
PRX08066
|
866206-55-5 |
PRX-866
|
CS-2323;5-[[4-[(6-氯噻吩并[2,3-D]嘧啶-4-基)氨基]-1-哌啶基]甲基]-2-氟-苯甲腈(2Z)-2-丁烯二酸盐
|
C23H21ClFN5O4S |
517.960343 |